V

Viatris
D

VTRS

11.260
USD
0.20
(1.76%)
مغلق
حجم التداول
338,716
الربح لكل سهم
3
العائد الربحي
4.27
P/E
-15
حجم السوق
13,439,856,077
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    1.200
    (0.60%)
    202.140 USD
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    JNJ
    JNJ
    2.680
    (1.68%)
    162.370 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    NVO
    NVO
    4.355
    (5.20%)
    88.090 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    SNY
    SNY
    0.325
    (0.60%)
    54.445 USD
    المزيد
الأخبار
المقالات

العنوان: Viatris

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.